MEK and ERK signaling are biologically the closest downstream point from RAS
and RAF activation; as a result, there is considerable interest in the use of MEK
inhibitors in the KRAS mutant population. The evidence of significant synergism
and activity of these molecules in combination with RAF inhibition in other subtypes has led to the development of several MEK inhibitors; some as noted below
have been explored in KRAS mutant NSCLC.
